Given that efforts to develop pharmacological inhibitors of glucagon receptor signaling as a therapy for hyperglycemia in T2DM continue (26, 27, 40), it is critical to understand the potential consequences of blocking glucagon receptor signaling at the adipocyte. Here, GCGR is linked to Hyperglycemia.